Volume | 5,363 |
|
|||||
News | - | ||||||
Day High | 4.3999 | Low High |
|||||
Day Low | 4.25 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
CalciMedica Inc | CALC | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.3287 | 4.25 | 4.3999 | 4.3399 | 4.39 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
81 | 5,363 | $ 4.30 | $ 23,052 | - | 1.75 - 8.59 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:58:24 | 33 | $ 4.27 | USD |
CalciMedica Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
24.67M | 5.68M | - | 0 | -34.36M | -6.04 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
CalciMedica News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CALC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.37 | 4.59 | 4.25 | 4.41 | 16,722 | -0.0301 | -0.69% |
1 Month | 3.66 | 4.59 | 3.3101 | 4.17 | 18,363 | 0.6799 | 18.58% |
3 Months | 5.12 | 8.38 | 3.3101 | 4.82 | 23,826 | -0.7801 | -15.24% |
6 Months | 2.235 | 8.38 | 1.75 | 4.05 | 19,770 | 2.10 | 94.18% |
1 Year | 4.70 | 8.59 | 1.75 | 3.88 | 18,818 | -0.3601 | -7.66% |
3 Years | 5.27 | 8.59 | 1.75 | 4.02 | 19,713 | -0.9301 | -17.65% |
5 Years | 5.27 | 8.59 | 1.75 | 4.02 | 19,713 | -0.9301 | -17.65% |
CalciMedica Description
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases. CRAC channels serve to replenish calcium levels in the endoplasmic reticulum (ER) and provide calcium for cellular signaling events. Its lead product candidate, Auxora, is an intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has the capability to modulate the immune response and protect against tissue cell injury, addressing inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure. |